GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018
- Data supports expanding use of GMI-1271 in patients with AML who are unfit for chemotherapy
- GMI-1359 shows potential in treating osteosarcoma and other cancers
Key findings from the preclinical research include:
- GMI-1271 could potentially be used with a hypomethylating agent, such as 5-azacitidine, to treat AML patients not healthy enough for intensive chemotherapy.
- In preclinical models, GMI-1359 mobilized tumor-reactive T-cells from bone marrow, which could enhance effectiveness of treatments despite tumor resistance.
- Both tumor growth and metastasis of osteosarcoma to lung tissue are reduced with GMI-1359 treatment.
“We are delighted to be able to share new data on potential expanded
uses of our candidates GMI-1271 and GMI-1359 at the 2018 AACR Annual
Details of the AACR presentations include:
Abstract #3514—Smith, T.A.G., et al. “Glycomimetic antagonist of
E-selectin, GMI-1271, enhances therapeutic activity of the
hypomethylating agent 5-azacitidine in the KG1 model of AML.”
Abstract #5435—Fogler, W.B., et al. "Mobilization of
tumor-primed, marrow infiltrating lymphocytes into peripheral blood with
inhibitors of E-selectin or E-selectin and CXCR4."
Abstract #6334—Ju, W., et al. “Dual E-selectin and CXCR4
inhibition reduces tumor growth and metastatic progression in an
orthotopic model of osteosarcoma.”
The AACR Annual Meeting 2018 takes place from
GMI-1271 is expected to enter Phase 3 clinical development in the third quarter of 2018. The molecule is designed to block E-selectin, an adhesion molecule on cells in the bone marrow, from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. In a completed Phase 1/2 clinical trial, the results of which were presented at the ASH 2017 meeting , both newly diagnosed elderly and relapsed/refractory patients with acute myeloid leukemia (AML) treated with GMI-1271, together with standard chemotherapy, achieved better than expected remission rates and overall survival compared to historical controls, which have been derived from results from third-party clinical trials, as well as lower than expected induction-related mortality rates and incidence of severe mucositis. Treatment in these patient populations was generally well tolerated, with fewer than expected adverse effects.
GMI-1359 is currently in Phase 1 testing in healthy volunteers. GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4. E-selectin and CXCR4 are both adhesion molecules that keep cancer cells in the bone marrow and affect cancer cell trafficking. Preclinical studies indicate that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that involve the bone marrow such as AML and multiple myeloma or in solid tumors that metastasize to the bone, such as prostate cancer and breast cancer.
GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of GMI-1271 and GMI-1359, including the expected
timing of completion of clinical trials and the presentation of
pre-clinical data. Actual results may differ materially from those in
these forward-looking statements. For a further description of the risks
associated with these statements, as well as other risks facing